1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug

Rivals Novartis and Amgen are already in Phase III with Lp(a) drugs

 
• By Jessica Merrill

The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.

race
Silence is further behind Novartis and Amgen to develop a drug to treat Lp(a). • Source: Shutterstock

An advancing area of cardiovascular-focused drug development – targeting lipoprotein(a), or Lp(a), to reduce risk of atherosclerotic cardiovascular disease (ASCVD) – is shaping up to be a competitive one dominated by big pharmas, and siRNA developer Silence Therapeutics plc would welcome a larger partner to advance its Lp(a) program zerlasiran into Phase III.

Key Takeaways
  • Silence therapeutics reported positive Phase II data for its Lp(a) program zerlasiran.
  • The category is shaping up to be a competitive one with bigger players, Novartis and Amgen, already in Phase III development

That said, CEO Craig Tooman said the company is prepared to move

More from Cardiovascular

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.